GlassScriptPhysician profile
Timothy J Blanchet
NPI 1053355172
$2,014.74
in general payments reported to CMS, 2019-2025
30 companies · $708 in 2025
The $708 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2022: $66.92 · 2023: $165 · 2024: $288 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $401.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $216.80 | 2019-2025 | |
| Lilly USA, LLC | $174.32 | 2019-2025 | Jardiance, Kisunla |
| Astrazeneca Pharmaceuticals LP | $164.24 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $113.42 | 2019-2025 | Repatha, Otezla |
| Exact Sciences Corporation | $105.47 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $85.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.81 | 2019 | |
| Merck Sharp & Dohme LLC | $61.68 | 2019-2024 | Vaxneuvance, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.98 | 2019 | |
| Supernus Pharmaceuticals, INC. | $50.34 | 2024-2025 | Qelbree |
| Glaxosmithkline, LLC. | $48.44 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $42.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $41.19 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $36.50 | 2023-2025 | Nexletol |
| Seqirus USA INC | $34.93 | 2025 | Flucelvax, Fluad |
| Abiomed | $31.32 | 2025 | |
| Arbor Pharmaceuticals, INC. | $26.28 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $26.01 | 2025 | Neffy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.42 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $22.05 | 2025 | Auvelity |
| Amarin Pharma, INC. | $21.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.63 | 2025 | Xifaxan |
| Abbvie INC. | $17.51 | 2025 | |
| Jazz Pharmaceuticals INC. | $15.94 | 2019 | |
| Bausch Health US, LLC | $15.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.58 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $13.48 | 2019 | |
| Shire North American Group INC | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Blanchet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.